AirSculpt Technologies (AIRS) Q2 2026 earnings summary

Executive summary

• Q2 2026 revenue was $42.9 million, down 2.5–3% year-over-year; six-month revenue was $82.3 million, down 1.3% year-over-year.

• Net loss for Q2 2026 was $1.1 million, compared to $0.6 million in Q2 2025; six-month net loss was $3.5 million, slightly higher than $3.4 million in 2025.

• Adjusted EBITDA for Q2 2026 was $4.9 million (11.5% margin), down from $5.8 million (13.3%) in Q2 2025.

• Case volume remained stable with 3,376 cases in Q2 2026 versus 3,392 in Q2 2025; same center case volume grew 1.0% in Q2 2026.

• Strategic initiatives included expanded procedure offerings, targeted marketing to GLP-1 patients, and new partnerships such as AlloClae.

Financial highlights

• Gross margin expanded to approximately 61% of revenue; cost of services was $16.6 million.

• Selling, general, and administrative expenses rose 3.3% in Q2 2026, mainly due to higher advertising costs.

• Interest expense dropped to $1.0 million in Q2 2026 from $1.6 million in Q2 2025 due to principal prepayments.

• Cash and cash equivalents were $18.8 million as of June 30, 2026, up from $8.2 million a year earlier.

• Ended Q2 with $44 million gross debt, in compliance with covenants, and extended loan maturity.

Outlook and guidance

• Full-year 2026 revenue expected at the lower end of $151–$157 million guidance; adjusted EBITDA outlook reduced to $12–$14 million.

• Q3 revenue expected to be down single digits year-over-year (excluding London); Q4 expected to show year-over-year growth in revenue and adjusted EBITDA.

• Guidance assumes stable macroeconomic conditions and excludes contributions from new procedures like AlloClae.

• Management expects operating cash flow and available credit to cover liquidity needs for at least the next 12 months.